TOWN AND COUNTRY PLANNING (SCOTLAND) ACT 1972

TAYSIDE STRUCTURE PLAN 1988 - ALTERATION NO 3

TAYSIDE INDICATIVE FORESTRY STRATEGY

THE SECRETARY OF STATE proposes to modify the Tayside Indicative Forestry Strategy - Alteration No 3 to the Tayside Structure Plan 1988.

Certified copies of the Alteration and the proposed modifications have been deposited for public inspection at the Public Relations Office, Council Chambers (Ground Floor), Tayside House, 28 Crichton Street, Dundee DD1 3RT and at public libraries throughout Tayside Region.

The deposited documents are available for inspection free of charge during normal office hours. They may also be obtained on request from the Director of Planning at the above-mentioned address. Objections to the proposed modifications should be sent in writing to the Secretary, Scottish Office Environment Department, Room 6/79, New St Andrew's House, Edinburgh EH1 3SZ by 27th November 1992.

Objections should state the matter to which they relate and the grounds on which they are made. Forms for making objections are obtainable at the place where the documents have been deposited but objections need not be made on the form provided.

> M T Affolter Assistant Secretary

Scottish Office Environment Department New St Andrew's House Edinburgh 30th October 1992

(66)

DEPARTMENT OF HEALTH

MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Telephone 071-273 0422 or 0425

Product Licences Granted

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications (Non-Prescription Items)	Date of Authorisation
0001/0169	Ciba-Geigy PLC T/A Ciba Laboratories	Water for Injections Ph Eur	Water for Injections EP 100% v/v	Prescription Only Medicine (Except POM cases)	7th October 1992
000370290	The Wellcome Foundation Limited	Sudafed Linctus Sugar Free	Pseudoephedrine Hydrochloride BP 30 mg Dextromethorphan Hydrobromide EP 10 mg	Pharmacy Medicine (Except POM cases) Clinical Indications Sudafed Linctus is indicated for the symptomatic relief of upper respiratory tract disorders which ma benefit from a combination of a nasa decongestant and an antiussive.	
	Lilly Industries Limited T/A Eli Lilly and Company Limited	Humulin I Cartridge I.5 ml- 100 iu/ml Injection	Human Insulin (PRB) HSE 100.0 iu	Pharmacy Medicine (Except POM cases) Indication For the treatment of insulin- dependent diabetes mellitus. Administration Subcutaneous or intramuscular injection	22nd July 1992
0006/0278	Lilly Industries Limited T/A Eli Lilly and Company Limited	Humulin ml Cartridge 1.5 ml- 100 iu/ml Injection	Soluble Human Insulin (PRB) HSE 10.00 iu Isophane Human Insulin (PRB) HSE 90.00 iu	Pharmacy Medicine (Except POM cases) Indication For the treatment of insulin- dependent diabetes mellitus. Administration Subcutaneous or intramuscular injection	22nd July 1992
0006/0279	Lilly Industries Limited T/A Eli Lilly and Company Limited	Humulin M2 Cartridge 1.5 ml- 100 iu/ml Injection	Soluble Human Insulin (PRB) HSE 20.00 iu Isophane Human Insulin (PRB) HSE 80.00 iu	Pharmacy Medicine (Except POM cases) Indication For the treatment of insulin- dependent diabetes mellitus. Administration Subcutaneous or intramuscular injection	22nd July 1992
1006/0280	Lilly Industries Limited T/A Eti Lilly and Company Limited	Humulin M3Cartridge 1.5 ml- 100 iu/ml Injection	Soluable Human Insulin (PRB) HSE 30.00 iu Isophane Human Insulin (PRB) HSE 70.00 iu	Pharmacy Medicine (Except POM cases) Indication For the treatment of insulin- dependent diabetes mellitus. Administration Subcutaneous or intramuscular injection	22nd July 1992
0006/0281	Lilly Industries Limited T/A Eli Lilly and Company Limited	Humulin M4 Cartridge 1.5 ml- 100 iu/ml Injection	Soluble Human Insulin (PRB) HSE 40.00 iu Isophane Human Insulin (PRB) HSE 60.00 iu	Pharmacy Medicine (Except POM cases) Indication For the treatment of insulin- dependent diabetes mellitus. Administration Subcutaneous or intramuscular injection	22nd July 1992